Potency

 

Velphoro is 2.6x more powerful than 1 tablet of sevelamer*1

 

Phosphate binder equivalent dose (PBED) relative to Velphoro (%)*1

Bar graph shows that Velphoro is more potent than sevelamer, ferric citrate, lanthanum, or calcium-based binders.

 

*Based on an analysis of comparative clinical studies that roughly established an equivalent dose for phosphate binders relative to the phosphate binding capacity of calcium carbonate.1

 

See the mechanism behind Velphoro potency

Phosphate is ingested and distributed throughout the body. Velphoro is highly selective for phosphorus in the pH range of the digestive tract (1.2 to 7.5).2 Phosphate from food binds to form phosphate-Velphoro complex, which is then excreted through the large intestine.3

More than 40% of patients are not at goal, indicating the ongoing challenge of phosphate management4-7

 

2/3 of patients have phosphorus levels beyond the KDIGO normal range4,5

DOPPS=Dialysis Outcomes and Practice Patterns Study

KDIGO=Kidney Disease: Improving Global Outcomes

References: 1. Coyne DW, Larson DS, Delmez JA. Bone disease. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 5th ed. Wolters Kluwer Health; 2015:665-692. 2. Wilhelm M, Gaillard S, Viatcheslav R, Funk F. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol. 2014;(81)4:251-258. 3. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America; 2020. 4. Dialysis Outcomes and Practice Patterns Study Program. DOPPS Practice Monitor. Serum phosphorus (most recent) categories. https://www.dopps.org/DPM/Files/phosphmgdl_c_overallTAB.htm. Accessed May 25, 2021. 5. Kidney Disease: Improving Global Outcomes. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2017;7(suppl 1):1-59. 6. Kidney Disease: Improving Global Outcomes. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009;76(suppl 113):1-140. 7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-S201. 8. Dialysis Outcomes and Practice Patterns Study Program. DOPPS Practice Monitor. Phosphate binder use, by type. https://www.dopps.org/DPM/Files/pbgroup_c_overallTAB.htm. Accessed May 25, 2021. 9. Data on file. Fresenius Medical Care North America, Waltham, MA.